BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AFSSI Sciences de la Vie - ECPv5.14.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AFSSI Sciences de la Vie
X-ORIGINAL-URL:https://www.afssi.fr
X-WR-CALDESC:Events for AFSSI Sciences de la Vie
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231026
DTEND;VALUE=DATE:20231028
DTSTAMP:20260427T014626
CREATED:20230404T123120Z
LAST-MODIFIED:20230811T095851Z
UID:200742-1698278400-1698451199@www.afssi.fr
SUMMARY:Conference Enzymatic Biocatalysis For Industry
DESCRIPTION:Enzynov’2 – Enzymatic Biocatalysis For Industry\nUnleashing the power of Enzymes and Biocatalysis for industrial applications \nOctober 26-27\, 2023  |  Biocitech\nRomainville-Paris\, Metro Line 5 Bobigny-Pantin-Raymond Queneau\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nEnzymes are biological activators increasingly used in various industrial sectors. Over the past years\, enzymes have gained in specificity and activity thanks to the development of genetic and metabolic strain engineering and synthetic biology. \nThe international scientific conference and Networking Forum  Enzynov’2 – Enzymes for industrial applications will focus on the utilization of enzymes and biocatalysis technologies in achieving more sustainable and productive industrial applications (chemistry\, cosmetics\, pharma\, food\, detergents\, others…). State of the art of the technology\, major market drivers according to sectors and manufacturing challenges linked to enzyme large–scale production or custom–designed enzymes\, as well as disruptive innovations will be discussed. \nOne key objective of this Symposium and networking forum convention is to promote the development of partnerships between large–scale enzyme industrial producers\, innovative start–ups and end users across a variety of industrial sectors (food\, chemistry\, drugs\, detergents…) \nSpeakers : the conference will feature speakers from both prestigious academic institutions and industry (mature international Companies and start–ups) in a convenient format leaving lots of time for discussions and business exchanges. \nVenue : Biocitech site and 250 seats auditorium is very easy to reach by metro from Paris Gare du Nord or Gare de l’Est train stations (35 minutes)\, as well as from the Paris Charles de Gaulle airport. Hotel accommodation and parking is available 5 min walk from the Biocitech facilities. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nInscription
URL:https://www.afssi.fr/event/enzynov2/
LOCATION:Biocitech Romainville\, 102 Avenue Gaston Roussel\, Romainville\, 93230\, France
CATEGORIES:Evénement partenaire
ATTACH;FMTTYPE=image/png:https://www.afssi.fr/wp-content/uploads/2023/04/Template-ENZYNOV2-PNG.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231026T170000
DTEND;TZID=Europe/Paris:20231026T170000
DTSTAMP:20260427T014626
CREATED:20231005T075333Z
LAST-MODIFIED:20231009T074630Z
UID:232067-1698339600-1698339600@www.afssi.fr
SUMMARY:Webinar ProteoGenix - The use of phage display for human antibody development
DESCRIPTION:Overcome the Multiple Challenge of Neutralizing Antibodies in Cancer Therapy Using Innovative Phage Display Technologies\nWhile Phage Display panning on naïve libraries combined with costly affinity maturation strategies have allowed the successful development of neutralizing antibodies\, it also leads to failures and aborted projects. One reason for this is the immune tolerance of a naïve library that is sometimes ineffective at identifying binders against important and/or highly expressed human targets. An efficient way to access high-affinity\, fully human antibodies against such targets is thus essential for human cancer therapy. \n\n\n\n  \nIn this webinar\, ProteoGenix will discuss innovative technologies to develop such antibodies using human phage display. These strategies include: \n\nA cross-panning protocol for a successful identification of neutralizing binders.\nPhage display libraries to allow an efficient identification of neutralizing binders through competitive ELISA.\nA new human cancer library constructed from the PBMCs of cancer patients as an efficient solution to counter immune tolerance.\n\n\n\n\n\nKey Topics Include:\n\n\nEfficient identification of neutralizing antibodies\nStrategic development of human phage libraries to break immune tolerance\nStrategies to augment phage display-based discovery\n\n\n\n\nSpeaker\n\nConor McCartin\, PhD\, Account Manager Monoclonal Antibody Development\, ProteoGenix\n\nAbout ProteoGenix\nFounded in 2003\, ProteoGenix has evolved from its roots in developing diagnostic assays and biotherapeutics to become a leading contract research organization and a trusted partner in the biopharma industry. With a focus on high-quality antibodies and proteins\, the company plays a pivotal role in advancing biomolecules from early discovery to clinical applications. Offering comprehensive services in six key areas—antibody engineering\, bioprocess development\, monoclonal and polyclonal antibody development\, recombinant protein and antibody production\, gene synthesis\, and peptide synthesis—ProteoGenix is a one-stop solution for researchers and developers. With over 15 years of experience\, innovative R&D contributions like the XtenCHO™ cell line\, and an extensive catalog of over 200\,000 products\, ProteoGenix stands as a cornerstone in the life sciences community\, dedicated to improving the success rate of clinical applications in biopharma. \n  \nRegistration
URL:https://www.afssi.fr/event/webinar-use-phage-display-human-antibody-development/
LOCATION:en ligne\, France
CATEGORIES:Evénement filière,Evénement partenaire
ATTACH;FMTTYPE=image/png:https://www.afssi.fr/wp-content/uploads/2023/10/Webinaire-ProteoGenix.png
END:VEVENT
END:VCALENDAR